drugset / Trial / NCT05190068
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Timeline
- Start
- 2022-01-04
- Primary completion
- 2025-01-27
- Completion
- 2025-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMPL-760 | Unknown | 50 mg | Oral |
| Subject | HMPL-760 | Unknown | 100 mg | Oral |
| Subject | HMPL-760 | Unknown | 200 mg | Oral |
| Subject | HMPL-760 | Unknown | 300 mg | Oral |
| Subject | HMPL-760 | Unknown | 400 mg | Oral |